afamelanotide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-07-23. Numbers and descriptions here follow the published literature rather than marketing material.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic cyclic heptapeptide | Alpha-MSH analogue containing a D-phenylalanine residue |
| Molecular formula | C50H69N15O9 | Average molecular mass approximately 1024.2 g/mol |
| Appearance | White to off-white lyophilised powder | Normally supplied as a freeze-dried solid in a sealed vial |
| Solubility | Freely soluble in water and polar solvents | Dissolves readily in aqueous buffers and in alcohol-water mixtures |
| Receptor targets | MC1R, MC3R, MC4R, MC5R | Acts as a non-selective melanocortin receptor agonist |
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
== Complications == LA-ICP-MS function optimally with gold particles greater than 60 μm in diameter to avoid any contamination during measurements. Although LA-ICP-MS has a lower detection limit, its overall precision was lower than other analysis techniques for trace element concentrations such as field emission-electron probe microanalysis (FE-EPMA) and synchrotron micro X-ray fluorescence spectroscopy (SR-l-XRF). Due to the small size of gold (<5μm-250μm) small fragments of minerals need to be separated from the gold before analysis can occur. Gold fingerprinting has limitations including elemental fractionation (the non-sample related analyte) and calibration requires matrix-matched standards. A few other problems exist that limit actual sourcing or provencancing of gold in relation to manufactured art objects. These problems include: a lack of an extensive database of elemental profiles in gold ores, the natural differences that coexist in ore geology and the difficulties of accurately analyzing trace elements. Also, trading, looting and re-melting of so called “precious” metal objects add to the problem of sourcing.
{\displaystyle {\begin{aligned}&{\frac {dS}{dt}}=-{\frac {\beta IS}{N}},\\[6pt]&{\frac {dI}{dt}}={\frac {\beta IS}{N}}-\gamma I-\mu I,\\[6pt]&{\frac {dR}{dt}}=\gamma I,\\[6pt]&{\frac {dD}{dt}}=\mu I,\end{aligned}}}
Health Minister Simeon Brown confirms the Government would lower the bowel screening eligibility age range from 60 to 58 years, using funding from a cancelled pilot programme established by the previous Labour government to lower the eligibility age for Māori and Pasifika New Zealanders from 60 to 50 years. Air New Zealand CEO Greg Foran announces that he will resign from his position effective 20 October. 7 March: New Zealand Labour Party leader Chris Hipkins announces a cabinet reshuffle of his shadow cabinet during his State of the Nation speech. Health Minister Simeon Brown announces a major overhaul of Health New Zealand including reinstating its leadership board, decentralisation and promoting private-public partnership. 8 March: A Pride parade is held in Wellington, with Mayor of Wellington Tory Whanau and actor Karen O'Leary attending. About 30 Destiny Church Man Up protesters stage a counter-protest. Police separate the two groups. A total fire ban comes into force in the Northland Region from 12am midnight in response to persistent dry, hot and windy conditions. 11 March – School lunch provider Libelle Group goes into liquidation, affecting 500 staff. The company had been contracted by the Compass Group to provide 125,000 meals to the Government's "Ka Ora, Ka Ako" school meal programme. 12 March: Camilla Belich's Crimes (Theft By Employer) Amendment Bill passes its third reading in Parliament with the support of the Labour, Green, Te Pāti Māori and New Zealand First.
== O == Obex The point in the brainstem where the fourth ventricle narrows to become the central canal of the spinal cord. Used as an anatomical landmark in neuroanatomy. Occipital lobe The rearmost lobe of the cerebral cortex, primarily responsible for visual processing, including interpretation of color, motion, and spatial orientation. Ocular dominance A preference of neurons in the visual cortex for input from one eye over the other. Studied extensively in visual development and plasticity. Oculomotor nerve (Cranial Nerve III) A cranial nerve that controls most of the eye's movements, including those of the eyelid and pupil constriction. Damage may result in diplopia or ptosis. Olfaction The sense of smell, mediated by receptors in the olfactory epithelium and processed in the olfactory bulb and related brain regions. Olfactory bulb The first brain structure to process olfactory (smell) information. Receives input from sensory neurons in the nasal cavity and sends projections to the olfactory cortex and limbic system. Olfactory cortex A region of the brain involved in odor identification and perception. Includes the piriform cortex and parts of the amygdala and entorhinal cortex. Olfactory nerve (Cranial Nerve I) The first cranial nerve, responsible for transmitting smell information from the nose to the brain. Oligodendrocyte A type of glial cell in the central nervous system that forms the myelin sheath around axons, enabling rapid signal conduction.
Sources: en.wikipedia.org
Industry, constituting 19.74% of GDP and 24% of total employment, is the second-largest sector. Large-scale manufacturing (LSM) dominates, representing 12.2% of GDP, with cement production thriving due to demand from Afghanistan and the domestic real estate sector. In 2013, Pakistan exported 7,708,557 metric tons of cement, with an installed capacity of 44,768,250 metric tons. The textile industry, a key player in Pakistan's manufacturing, contributes 9.5% to GDP and employs around 15 million people. As of 2022, Pakistan ranks seventh globally in cotton production, with substantial spinning capacity, making it a major exporter of textile products in Asia. China has been a significant buyer of Pakistani textiles, importing US$1.527 billion worth of textiles in 2012.
=== Atopic dermatitis === If topical corticosteroids and moisturisers fail in the treatment of atopic dermatitis, short-term treatment with topical calcineurin inhibitors such as tacrolimus or pimecrolimus may be tried. Both tacrolimus and pimecrolimus are effective and safe to use in AD.
=== Early detection === From May to August 1939 the LZ130 Graf Zeppelin II made flights along Britain's North Sea coast to investigate the 100-metre-high radio towers that were being erected from Portsmouth to Scapa Flow. LZ130 performed a series of radiometric tests and took photographs. German sources report the 12 m Chain Home signals were detected and suspected to be radar; however, the chief investigator was not able to prove his suspicions. Other sources are said to report different results. During the Battle of France, the Germans observed 12 m pulse signals on the western front without being able to recognize their origin and purpose. In mid-June 1940, the Deutsche Versuchsanstalt für Luftfahrt (DVL, German Aeronautic Research Institute) set up a special group under the direction of Professor von Handel and found out that the signals originated from the installations on the coast of the English Channel. Their suspicions were finally proven in the aftermath of the Battle of Dunkirk, when the British were forced to abandon a mobile gun-laying radar (GL Mk. I) station in Normandy. Wolfgang Martini's team of specialists was able to determine the operation of the system. GL was a rather crude system of limited effectiveness, and this led the Germans to have a dim view of British radar systems. However, an effective system requires more than just the radar; plotting and reporting are equally important, and this part of the system was fully developed in Chain Home.
Locals are "Districts"; national convention meets quadrennially; headquarters in Pittsburgh; in 1979 had $120,000,000 in insurance; also sponsored outings, baseball games, etc. While originally for German men and women, by 1979 the Union was open to men and women of all ethnic backgrounds. In 1923 the Union had 54,000 members, 50,000 in 1965, and 37,000 in 1979. Improved Order, Knights of Pythias Independent Order of Red Men North American Swiss Alliance - Founded July 14, 1865, as the Grütli Bund der Vereinigten Staaten von Nord Amerika in Cincinnati. Became Nordamerikanishcher Schweizerbund in July 1911. National convention meets quadrennially, locals are called branches or lodges. Open to Swiss, Swiss descendants, or spouses of Swiss. Membership 2,000 in 1965, 4,000 in 1978 and 3,350 in 1994, about 10 to 15% are social, uninsured members. Periodical originally called Gruetlianer changed to Der Schweizer in 1911. Headquarters in Cleveland in 1979, but it was an "organization on wheels" moving to several places every few years in the late 19th century Schwarzer Ritter, Deutscher Orden - Claimed great antiquity, though in 1899 it was said to have been present in the United States for about 30 years. Active in New York, New Jersey, Pennsylvania, and the District of Columbia. Sons of Hermann United League of America Workmen's Benefit Fund - Founded as the Workmen's Sick and Death Benefit Fund in 1884, this organization was licensed to provide insurance in February 1899. The current name was adopted in 1939. Membership opened to non-Germans in 1976.
=== Metabolic/biochemical genetics === Metabolic (or biochemical) genetics involves the diagnosis and management of inborn errors of metabolism in which patients have enzymatic deficiencies that perturb biochemical pathways involved in metabolism of carbohydrates, amino acids, and lipids. Examples of metabolic disorders include galactosemia, glycogen storage disease, lysosomal storage disorders, metabolic acidosis, peroxisomal disorders, phenylketonuria, and urea cycle disorders.
Sources: en.wikipedia.org
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.
No approved regulatory indication exists in major markets. An approval exists for a different peptide, afamelanotide, which is used for a rare photosensitivity disorder called erythropoietic protoporphyria. Melanotan-2 itself remains a research compound with no cleared clinical role.
Melanocortin-1 receptors on melanocytes are the receptor most closely linked to pigment production. The peptide is not selective, however, and also activates melanocortin-3, melanocortin-4, and melanocortin-5 receptors. That lack of selectivity is the usual explanation offered for both its range of observed effects and its off-target effects.
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.